(Total Views: 129)
Posted On: 10/04/2025 8:21:27 PM
Post# of 8694
DARPA’s BioElectronics to Sense and Treat (BEST) program has officially commenced. The program is focused on developing wearable, automated smart bandages capable of:
Predicting and preventing wound infections
Monitoring healing in real time
Delivering targeted treatment via closed-loop bioelectronic control
The program is actively seeking teams with technologies ready for Technology Readiness Level 6 (TRL-6), which includes system-level integration and testing. DARPA has allocated $22.8 million for selected performers, and proposals are being accepted through the official solicitation process.
As for BIEL (BioElectronics Corporation), while there’s no public confirmation yet that they’ve been selected as a performer or subcontractor, their RecoveryRx and ActiPatch technologies—particularly their use of Pulsed Shortwave Therapy (PSWT)—appear to align well with DARPA’s goals. Their FDA-cleared, wearable, and non-invasive devices, along with their vagus nerve stimulation patent application, could position them as a strong candidate for collaboration.
If BIEL is chosen, the strategic implications —funding, validation, expanded military and VA adoption, and potential valuation boost—are all realistic outcomes. For now, the BEST program is underway, and the next key milestone would be DARPA’s announcement of selected performers.
Predicting and preventing wound infections
Monitoring healing in real time
Delivering targeted treatment via closed-loop bioelectronic control
The program is actively seeking teams with technologies ready for Technology Readiness Level 6 (TRL-6), which includes system-level integration and testing. DARPA has allocated $22.8 million for selected performers, and proposals are being accepted through the official solicitation process.
As for BIEL (BioElectronics Corporation), while there’s no public confirmation yet that they’ve been selected as a performer or subcontractor, their RecoveryRx and ActiPatch technologies—particularly their use of Pulsed Shortwave Therapy (PSWT)—appear to align well with DARPA’s goals. Their FDA-cleared, wearable, and non-invasive devices, along with their vagus nerve stimulation patent application, could position them as a strong candidate for collaboration.
If BIEL is chosen, the strategic implications —funding, validation, expanded military and VA adoption, and potential valuation boost—are all realistic outcomes. For now, the BEST program is underway, and the next key milestone would be DARPA’s announcement of selected performers.
(1)
(0)
